Dactinomycin - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for dactinomycin and what is the scope of freedom to operate?
Dactinomycin
is the generic ingredient in two branded drugs marketed by Recordati Rare, Am Regent, Eugia Pharma, Hikma, Hisun Pharm Hangzhou, Meitheal, and Xgen Pharms, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.There are three drug master file entries for dactinomycin. Six suppliers are listed for this compound.
Summary for dactinomycin
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 7 |
NDAs: | 7 |
Drug Master File Entries: | 3 |
Finished Product Suppliers / Packagers: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 39 |
Clinical Trials: | 47 |
Patent Applications: | 2,820 |
Drug Prices: | Drug price trends for dactinomycin |
What excipients (inactive ingredients) are in dactinomycin? | dactinomycin excipients list |
DailyMed Link: | dactinomycin at DailyMed |
Recent Clinical Trials for dactinomycin
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
St. Jude Children's Research Hospital | Phase 1/Phase 2 |
xiang yang | N/A |
University of Birmingham | Phase 1/Phase 2 |
Pharmacology for dactinomycin
Drug Class | Actinomycin |
Mechanism of Action | Nucleic Acid Synthesis Inhibitors Protein Synthesis Inhibitors |
Medical Subject Heading (MeSH) Categories for dactinomycin
Anatomical Therapeutic Chemical (ATC) Classes for dactinomycin
US Patents and Regulatory Information for dactinomycin
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Am Regent | DACTINOMYCIN | dactinomycin | INJECTABLE;INJECTION | 202562-001 | Aug 23, 2013 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Meitheal | DACTINOMYCIN | dactinomycin | INJECTABLE;INJECTION | 213463-001 | Nov 13, 2020 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Xgen Pharms | DACTINOMYCIN | dactinomycin | INJECTABLE;INJECTION | 203999-001 | May 20, 2019 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Eugia Pharma | DACTINOMYCIN | dactinomycin | INJECTABLE;INJECTION | 203385-001 | Nov 9, 2017 | AP | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.